Digest Network Come funziona
Network
/
Società
Ve
Non verificato

Ventus Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

10 comunicati stampa

Guarda tutti i comunicati
21/10/2025
Industria
Biotecnologia
Farmaceutica
Salute
Tecnica
Medicina - Varie
Ventus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus' ReSOLVE® Platform
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
04/09/2025
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Eventi
Ventus Therapeutics to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
22/05/2025
Fiere
Eventi
Finanza
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
29/04/2025
Eventi
Fiere
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
25/03/2025
Industria
Salute
Scienza
Medicina - Varie
Farmaceutica
Biotecnologia
Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
10/03/2025
Industria
Scienza
Sanità
Farmaceutica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Salute
Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
06/03/2025
Industria
Scienza
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
19/02/2025
Salute
Sanità
Farmaceutica
Biotecnologia
Mercato del lavoro
Ventus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical Officer
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
31/10/2024
Attrezzature medico-sanitarie
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0
16/07/2024
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sanità
Industria
Ventus Therapeutics Significantly Expands its Presence in Montreal, Canada with Opening of a New Laboratory and Office Facility
Fonte
Ventus Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0